It's going to be awhile for K to finish p2, ready for p3. As he said to me personally and a room full of people at Biotech in January: 'This is the year of partnerships.' I take him on his word for it, but that's me. Plus another minimum of 4 drugs being perfected now for p1 gives us another hint. I would keep an eye on Pfizer since we have three new hires from the company. Never know. It will be interesting.

$8b? What could that do for shareholders in your opinion? Any speculation?